Myriad Genetics has expanded collaboration with AbbVie to accelerate development of the latter’s investigational PARP inhibitor, veliparib.

The companion diagnostics (CDx) research collaboration builds on an existing partnership established in November 2014, in which Myriad and AbbVie are working to support Phase 3 clinical studies of veliparib for patients with breast cancer or ovarian cancer.

As part of the expanded partnership, AbbVie will use Myriad’s CDx portfolio, myChoice HRD, and new tumour tests to help identify patients with non-small cell lung cancer who are likely to respond to treatment with the combination of veliparib and chemotherapy.

Myriad Genetics chief scientific officer Jerry Lanchbury said: "As a company committed to innovation in the field of oncology, this collaboration with AbbVie enables us to use our proprietary companion diagnostics to advance care for patients with lung cancer.

"If we are successful, our companion diagnostics will identify more patients who may benefit from treatment with the combination of veliparib and chemotherapy."

"If we are successful, our companion diagnostics will identify more patients who may benefit from treatment with the combination of veliparib and chemotherapy."

In a separate development, Myriad has also entered into a research collaboration with Tesaro and Merck to evaluate treatment response in patients with triple negative breast cancer or ovarian cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The patients will be administered an investigational combination drug therapy using TESARO’s PARP inhibitor (niraparib) along with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab).

The treatment response will be evaluated by using Myriad’s myChoice HRD test and new tumour tests.

Since March 2014, Myriad has been working with TESARO to use the myChoice HRD test for identifying ovarian cancer patients who may respond to niraparib, which is in Phase III clinical development.